

## Committee annual report

(all cells can be expanded as needed)

### Committee chair

Name of committee : Transplantation committee		
Chair : Yves Beguin	Since : 11-2007	Date of last election : 27-06-2011

### Committee members : name (E-mail)

Baron Frédéric ( <a href="mailto:F.Baron@ulg.ac.be">F.Baron@ulg.ac.be</a> ) Beguin Yves ( <a href="mailto:yves.beguin@chu.ulg.ac.be">yves.beguin@chu.ulg.ac.be</a> ) Berneman Zwi ( <a href="mailto:zwi.berneman@ua.ac.be">zwi.berneman@ua.ac.be</a> ) De Becker Ann ( <a href="mailto:Ann.DeBecker@uzbrussel.be">Ann.DeBecker@uzbrussel.be</a> ) Deeren Dries ( <a href="mailto:DDeeren@hhr.be">DDeeren@hhr.be</a> ) Graux Carlos ( <a href="mailto:carlos.graux@uclouvain.be">carlos.graux@uclouvain.be</a> ) Herman Julie ( <a href="mailto:julie.herman.bhs@gmail.com">julie.herman.bhs@gmail.com</a> ) Kerre Tessa ( <a href="mailto:Tessa.Kerre@UGent.be">Tessa.Kerre@UGent.be</a> ) Lewalle Philippe ( <a href="mailto:philippe.lewalle@bordet.be">philippe.lewalle@bordet.be</a> ) Lodewyck Tom ( <a href="mailto:Tom.Lodewyck@azbrugge.be">Tom.Lodewyck@azbrugge.be</a> )	Maertens Johan ( <a href="mailto:Johan.Maertens@uz.kuleuven.ac.be">Johan.Maertens@uz.kuleuven.ac.be</a> ) Noens Lucien ( <a href="mailto:lucien.noens@UGent.be">lucien.noens@UGent.be</a> ) Ory Aurélie ( <a href="mailto:aurelie.ory@chu.ulg.ac.be">aurelie.ory@chu.ulg.ac.be</a> ) Poiré Xavier ( <a href="mailto:xavier.poire@uclouvain.be">xavier.poire@uclouvain.be</a> ) Schots Rik ( <a href="mailto:rik.schots@az.vub.ac.be">rik.schots@az.vub.ac.be</a> ) Schoemans Hélène ( <a href="mailto:helene.schoemans@uzleuven.be">helene.schoemans@uzleuven.be</a> ) Selleslag Dominik ( <a href="mailto:dominik.selleslag@azbrugge.be">dominik.selleslag@azbrugge.be</a> ) Straetmans Nicole ( <a href="mailto:nicole.straetmans@scarlet.be">nicole.straetmans@scarlet.be</a> ) Willems Evelyne ( <a href="mailto:E.Willems@chu.ulg.ac.be">E.Willems@chu.ulg.ac.be</a> ) Zachée Pierre ( <a href="mailto:pierre.zachee@zna.be">pierre.zachee@zna.be</a> )
---	---

### Activities in year 2014

Date	Activity
24-04-2014	Committee meeting
19-06-2014	Committee meeting
23-10-2014	Committee meeting
	<b>Main activities :</b> <ul style="list-style-type: none"> <li>- Preparation of reimbursement dossier for posttransplant vaccinations to be sent to INAMI/RIZIV in 2015</li> <li>- Preparation of reimbursement dossier for photopheresis to be sent to INAMI/RIZIV in 2015</li> <li>- Continuation of the Valcyte MNP</li> <li>- Writing of Belgian recommendations on posttransplant vaccinations</li> <li>- Analysis of TC01 clinical trial results (Allogeneic hematopoietic cell transplantation with HLA-matched donors : a phase II randomized study comparing 2 nonmyeloablative conditionings) and publication of results.</li> <li>- Hiring of 2 nd BHS CRA (Julie Herman, 0.5 FTE) to work on the Transplant Committee clinical trials</li> <li>- Ongoing clinical trials           <ul style="list-style-type: none"> <li>• TC02 : Infusion of mesenchymal stem cells as treatment for steroid resistant grade II to IV acute GVHD or poor graft function: a multicenter phase II study (01-2008)</li> <li>• TC03 : Co-transplantation of mesenchymal stem cells and HLA-mismatched allogeneic hematopoietic cells after nonmyeloablative conditioning: a phase II randomized double-blind study (07-2010)</li> <li>• TC04 : A pilot study to assess the feasibility of unrelated umbilical cord blood transplantation with coinfusion of third-party mesenchymal stem cells after myeloablative or nonmyeloablative conditioning in adult patients with hematological malignancies (11-2010)</li> <li>• TC05 : Randomized double-blind study of mesenchymal stem cells (MSC) in patients undergoing matched unrelated allogeneic bone marrow or peripheral blood stem cell transplantation -A European multicentre study (08-2010)</li> <li>• TC06 : Prevention and treatment of severe GVHD after allogeneic hematopoietic stem cell transplantation, applied as consolidation immunotherapy in patients with hematological malignancies. A prospective randomized phase III trial (10-2010)</li> <li>• TC07 : Allogeneic hematopoietic cell transplantation from HLA-matched donors after reduced-intensity conditioning: a phase II randomized study comparing 2 GVHD prophylaxis regimen (09-2011)</li> <li>• TC08 : Busulfan dosage in allogeneic stem cell transplant recipients receiving PO Busulfan containing conditioning regimens (07-2012)</li> </ul> </li> </ul>

	<ul style="list-style-type: none"> <li>• <b>TC09</b> : Wilms' tumor (WT1) antigen-targeted dendritic cell vaccination to prevent relapse in patients older than 65 years with acute myeloid leukemia: a multicenter randomized phase II trial (06-2013)</li> <li>• <b>TC10</b> : Sequential administration of 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (12-2013)</li> <li>• <b>TC11</b> : A phase II study to assess the safety and the efficacy of extracorporeal photopheresis using the Theraflex ECPTM for patients with refractory chronic GVHD (09-2014)</li> </ul> <p>- <b>Activities of the Belgian Transplant Registry (BTR) in collaboration with the Cancer registry and EBMT</b></p> <ul style="list-style-type: none"> <li>* Descriptive analysis of transplant activity in Belgium 2007-2011; this will be completed by 02-2015 with a full report.</li> <li>* Preparation of outcome analyses to be performed in 2015 on the 2007-2012 transplant activity in Belgium and evaluation of each individual transplant center</li> <li>* Preparation of an evaluation of Belgium compliance with EBMT transplant indications to be performed in 2015 on the 2007-2012 transplant activity in Belgium and evaluation of each individual transplant center</li> </ul>
<p><b>! Please provide minutes of all this year's committee meetings !</b></p>	

### **Publications in year 2014**

1. Moors I, Schoemans H, Callens S, Beguin Y, Kerre T. Vaccination guidelines in hematopoietic transplant patients: recommendations from the BHS Transplant Committee. *Belgian J. Hematol.* 6:44-54, 2014.
2. Baron F, Zachée P, Maertens J, Kerre T, Ory A, Seidel L, Graux C, Lewalle P, Van Gelder M, Theunissen K, Willems E, Emonts M-P, Schots R, Beguin Y. Nonmyeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society. *J.Hematol.Oncol.*, in press.
3. Hannon M, Beguin Y, Ehx G, Servais S, Seidel L, Graux C, Maertens J, Kerre T, Daulne C, De Bock M, Fillet M, Ory A, Willems E, Gothot A, Humblet-Baron S, Baron F. *Immune recovery after allogeneic hematopoietic stem cell transplantation following Flu-TBI versus TLI-ATG conditioning.* Submitted

### **Plan (policy, activities with approximate dates...) for next year**

- **Continuation of ongoing clinical trials**
- **Pilot clinical trial of total marrow irradiation as conditioning before transplantation**
- **Submission to RIZIV/INAMI of the files on reimbursement of (1) posttransplant vaccinations and (2) photopheresis**
- **Performance of analyses of outcome and of transplant indications on the 2007-2012 Belgian transplant activity and writing of a full report**
- **Analysis of TC02 clinical trial results (Infusion of mesenchymal stem cells as treatment for steroid resistant grade II to IV acute GVHD or poor graft function: a multicenter phase II study), cohorts 1 (AGVHD) and 2 (poor graft function) and publication of results.**

### **Comments / requests for the BHS board**

**Thank you for the support in the form of 2 x 0.5 FTE data manager to manage all the ongoing clinical trials !**